PMVP

PMV Pharmaceuticals, Inc. [PMVP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PMVP Stock Summary

Top 10 Correlated ETFs

PMVP

Top 10 Correlated Stocks

PMVP

In the News

PMVP Financial details

Company Rating
-
Market Cap
92.08M
Income
-66.61M
Revenue
1.62M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-1.82
Forward P/E
-
PEG
1.4
P/S
-
P/B
0.54
P/C
-
P/FCF
-2.17
Quick Ratio
18.84
Current Ratio
19.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.4
EPS next Y
-
EPS next Q
-
EPS this Y
-10.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-8.82%
-
-
-
-
SMA20
-6.77%
SMA50
-12.68%
SMA100
-7.46%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-30%
ROC
-0.33%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.175-9.72
52W High
-86.28%
52W Low
+23.5%
RSI
42.6
Rel Volume
0.22
Avg Volume
565.82K
Volume
123.46K
Perf Week
-4.26%
Perf Month
-11.79%
Perf Quarter
6.47%
Perf Half Y
9.29%
-
-
-
-
Beta
1.64
-
-
Volatility
0.04%, 0.07%
Prev Close
-1.2%
Price
1.235
Change
-1.98%

Something similar

Top by Market Cap
APC.DE
1YD.DE
LLY.SW
VTSAX
AAPL
Top Correlated ETFs
GLIN
INQQ
SMIN
INDL
EPI
Top Correlated Stocks
HEMIPROP.NS
SEQUENT.NS
DHANBANK.NS
THYROCARE.NS
0I6Q.L
Similar Market Cap
VALT
0901.HK
BHR
LICY
0841.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 565.82K
  • Market Capitalization 92.08M
  • Employee 63
  • CEO Dr. David H. Mack Ph.D.
  • Headquarters Cranbury,NJ,US
  • IPO Date 2020-09-25
  • Website https://www.pmvpharma.com

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.